a study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia

Conditions: Achondroplasia

Summary: this is a phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ach) who have completed at least 26 weeks of participation in the qed-sponsored study propel (qbgj398-001).


Eligibility criteria:
inclusion criteria: 1. subject must be 3 to \ 1.5 cm/year over a period of at least 6 months of participation in the propel observational study (qbgj398-001), pubertal tanner stage ≤4, and bone age ≤13 years in females and ≤15 years in males. type of subject and disease characteristics 2. subjects who have a diagnosis of ach that has been documented clinically and confirmed by genetic testing. 3. subjects must have completed at least 26 weeks in the propel (qbgj398-001) study before screening. 4. subjects are able to swallow oral medication. 5. subjects and parent(s), legal guardian(s), or caregivers are willing and able to comply with study visits and study procedures. 6. subjects are ambulatory and able to stand without assistance. sex and contraceptive/barrier requirements 7. negative pregnancy test in girls ≥10 years of age or girls of any age who have experienced menarche. 8. if sexually active, subjects, whether male or female, must be willing to use a highly effective method of contraception while taking study drug and for 3 months after the last dose of study drug. informed consent 9. signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol, must be obtained for each subject from their parent(s) or legal guardian and signed informed consent/assent must be obtained from the subject (when applicable) exclusion criteria: medical conditions 1. subjects who have hypochondroplasia or short stature condition other than ach. 2. significant concurrent disease or condition that, in the view of the investigator and/or sponsor, would confound assessment of efficacy or safety of infigratinib. 3. current evidence of clinically significant corneal or retinal disorder/keratopathy -confirmed by ophthalmic examination. 4. concurrent circumstance, disease or condition that, in the view of the investigator and/or sponsor, would interfere with study participation or safety evaluations and/or would require treatment with a prohibited medication, and/or would place the subject at high risk for poor treatment compliance or for not completing the study. 5. history and/or current evidence of extensive ectopic tissue calcification. 6. history of malignancy. prior/concomitant therapy 7. having received or planning to receive treatment with any other investigational or approved product for the treatment of ach or short stature. 8. regular long-term treatment (≥3 weeks) with supraphysiologic doses of glucocorticoid therapy (ie, \>15 mg/m2/day of hydrocortisone or equivalent) or treatment with glucocorticoids at anti-inflammatory doses (ie, 2.5-10 mg/kg/day of hydrocortisone or equivalent) for over 3 weeks within 6 months of the screening visit (low-dose local preparations including inhaled steroid for asthma, intranasal sprays for allergies, and topical steroids are allowed). 9. previous limb-lengthening surgery at any time or planned/expected to have limb-lengthening surgery or guided growth surgery during the study period. guided growth surgery with plates removed at least 12 months prior to screening is allowed. 10. currently receiving treatment with agents that are known strong inducers or inhibitors of cyp3a4 or prolonged treatment (\>1 week) with medications that alter the ph of the gastrointestinal tract including antacids, h2 antagonists (eg, ranitidine, famotidine), and proton-pump inhibitors (eg, omeprazole). 11. current evidence of endocrine alterations of calcium/phosphorus homeostasis. diagnostic assessments 12. subjects who have significant abnormality in screening laboratory results. other exclusions 13. having had a fracture of the long bones (ie, extremities) or spine within 12 months prior to screening. 14. pregnant or breastfeeding at the screening visit or planning to become pregnant (self or partner) at any time during the study. 15. allergy or hypersensitivity to any components of the study drug.

Keywords: skeletal dysplasia endochondral ossification quality of life in achondroplasia fibroblast growth factor receptor 3 fgfr3 endochondral bone formation short-limb disproportionate dwarfism dwarfism bone disease functionality in achondroplasia musculoskeletal diseases osteochondrodysplasia genetic diseases long-term treatment growth annualized height velocity